% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wollring:916957,
      author       = {Wollring, Michael M. and Werner, Jan-Michael and Ceccon,
                      Garry and Lohmann, Philipp and Filss, Christian P. and Fink,
                      Gereon R. and Langen, Karl-Josef and Galldiks, Norbert},
      title        = {{C}linical applications and prospects of {PET} imaging in
                      patients with {IDH}-mutant gliomas},
      journal      = {Journal of neuro-oncology},
      volume       = {162},
      issn         = {0167-594x},
      address      = {Dordrecht [u.a.]},
      publisher    = {Springer Science + Business Media B.V},
      reportid     = {FZJ-2023-00223},
      pages        = {481-488},
      year         = {2023},
      abstract     = {PET imaging using radiolabeled amino acids in addition to
                      MRI has become a valuable diagnostic tool in the clinical
                      management of patients with brain tumors. This review
                      provides a comprehensive overview of PET studies in glioma
                      patients with a mutation in the isocitrate dehydrogenase
                      gene (IDH). A considerable fraction of these tumors
                      typically show no contrast enhancement on MRI, especially
                      when classified as grade 2 according to the World Health
                      Organization classification of Central Nervous System
                      tumors. Major diagnostic challenges in this situation are
                      differential diagnosis, target definition for diagnostic
                      biopsies, delineation of glioma extent for treatment
                      planning, differentiation of treatment-related changes from
                      tumor progression, and the evaluation of response to
                      alkylating agents. The main focus of this review is the role
                      of amino acid PET in this setting. Furthermore, in light of
                      clinical trials using IDH inhibitors targeting the mutated
                      IDH enzyme for treating patients with IDH-mutant gliomas, we
                      also aim to give an outlook on PET probes specifically
                      targeting the IDH mutation, which appear potentially helpful
                      for response assessment.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {36577872},
      UT           = {WOS:000905547600001},
      doi          = {10.1007/s11060-022-04218-x},
      url          = {https://juser.fz-juelich.de/record/916957},
}